A study of EnGeneIC Dream Vectors (EDV’s) packaged with the chemotherapy, E-EDV-D682 given simultaneously as non-targeted EDVs carrying an immune enhancer called EDV-GC, in participants with advanced epidermal growth factor expressing cancers whose disease has progressed after one or two treatment regimes, or where other standard therapies are not appropriate. (EGFR EDV-D682/GC Trial)
ACTRN 12625000203459 Brief Summary This study aims to determine whether E-EDV-D682 in…
Read more arrow_forward